

1. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human paraoxonase/arylesterase gene (PON1) is one member of a multigene family. *Genomics* 1996; 33: 498-507.
2. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BA. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. *J Biol Chem* 2000; 275 (43): 33435-33442.
3. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow, ed. *Pharmacogenetics of drug metabolism*. New York: Pergamon Press, 1992: 51-91.
4. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human paraoxonase polymorphism is reversed with diazoxon, soman and sarin. *Nat Genet* 1996; 14: 334-336.
5. Banka CL. High density lipoprotein and lipoprotein oxidation. *Curr Opin Lipidol* 1996; 7: 139-142.
6. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. *FEBS Lett* 1991; 286: 152-154.
7. Mackness MI, Arrol S, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. *Atherosclerosis* 1993; 104: 129-135.
8. Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. *Biochem J* 1993; 294: 829-834.
9. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. *Atherosclerosis* 1995; 115: 243-253.
10. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. The Yin and Yang of oxidation in the development of fatty streak. A review based of the 1994 George Lyman Duff Memorial Lecture. *Arterioscl Thromb Vasc Biol* 1996; 16: 831-842.

## Referències bibliogràfiques

---

11. Hayek T, Oiknine J, Dankner G, Brook JG, Aviram M. HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. *Eur J Clin Chem Clin Biochem* 1995; 33: 721-725.
12. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. *Drug Metab Dispos* 2000; 28: 1335-1342.
13. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. *J Nutr* 2000; 130: 377S-381S.
14. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with risk of coronary Herat disease. *Am J Hum Genet* 1998; 62: 36-44.
15. Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui LC, Hegele RA. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. *Atherosclerosis* 1998; 139: 131-136.
16. Mackness B, Durrington PN, Mackness MI. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. *Lancet* 1999; 353: 468-469.
17. Ng CJ, Waldeigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy S. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. *J Biol Chem* 2001; 276 (48): 44444-44449.
18. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. *J Biol Chem* 2000; 275: 33435-33442.
19. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. *Arterioscl Thromb Vasc Biol* 2001; 21: 542-547.
20. Hassett C, Richter R, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. *Biochemistry* 1991; 30: 10141-10149.

21. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. *Am J Hum Genet* 1983; 35: 214-227.
22. Hasselwander O, Mc Master D, Fogarty DG, Maxwell AP, Nicholls DP, Young IS. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. *Clin Chem* 1998; 44: 179-181.
23. Burlina A, Michielin E, Galzigna L. Characteristics and behaviour of arylesterase in human serum and liver. *Eur J Clin Invest* 1977; 7: 17-20.
24. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. *Eur J Clin Chem Clin Biochem* 1992; 30: 391-395.
25. Kawai H, Sakamoto F, Inoue Y. Improved specific assay for serum arylesterase using a water soluble substrate. *Clin Chim Acta* 1990; 188: 177-182.
26. Kawai H, Yomoda S, Inoue Y. ELISA using monoclonal antibody to human serum arylesterase. *Clin Chim Acta* 1991; 202: 219-226.
27. Blatter Garin MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase.. *Eur J Biochem* 1993; 211: 871-879.
28. Blatter Garin MC, Abbott C, Messmer S, Mackness M, Durrington P, Pometta D, James RW. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. *Biochem J.* 1994; 304: 549-554.
29. Abbott C, Mackness M, Kumar S, Boulton AJ, Durrington P. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. *Arterioscler Thromb Vascr Biol* 1995; 15: 1812-1818.
30. Playfer JR, Eze LC, Bullen MF, Evans DA. Genetic polymorphism and interethnic variability of plasma paraoxonase activity. *J Med Genet* 1976; 13: 337-342.
31. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. *Am J Hum Genet* 1983; 35: 1126-1138.

32. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. *Am J Hum Genet* 1993; 52: 598-608.
33. Blatter Garin MC, James RW, Dussoix P, Blanché H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. *J Clin Invest* 1997; 99: 62-66.
34. Leviev I, James RW. Promoter polymorphisms of human paraoxonase *PON1* gene and serum paraoxonase activities and concentrations. *Arterioscler Thromb Vasc Biol* 2000; 20: 516-521.
35. Brophy VH, Jampsa RL, Clendenning JB, Mckinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (*PON1*) expression. *Am J Hum Genet* 2001; 68: 1428-1436.
36. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Blatter Garin MC. Promoter polymorphism T(-107)C of the paraoxonase *PON1* gene is a risk factor for coronary heart disease in type 2 diabetic patients. *Diabetes* 2000; 49: 1390-1393.
37. Brophy VH, Hastings MD, Cendenning JB, Ritcher RJ, Jarvik GP, Furlong CE. *Pharmacogenetics* 2001; 11: 77-84.
38. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. *J Clin Invest* 1995; 96: 2882-2891.
39. Aviram M, Rosenblat M, Billecke S, Eroglu J, Sorenson R, Bisgaier CL, Newton RS, La Du B. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. *Free Rad Biol Med* 1999; 26: 892-904.
40. Kaplan M, Aviram M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. *Clin Chem Lab Med* 1999; 37: 777-787.
41. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. *J Clin Invest* 1998; 101: 1581-1590.

42. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. *Nature* 1998; 364: 284-287.
43. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. *J Biol Chem* 2000; 275: 17527-17535.
44. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. PON1 esterase and peroxidase-like activities. *Circulation* 2000; 101: 2510-2517.
45. Cao H, Girard-Globa A, Berthezene F, Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R genetic polymorphism. *J Lipid Res* 1999; 40: 133-139.
46. Ruiz J, Blanché H, James RW, Blatter Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. *Lancet* 1995; 346: 869-872.
47. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. *J Clin Invest* 1995; 96: 3005-3008.
48. Mackness B, Mackness MI, Durrington PN, Arrol S, Evans AE, McMaster D, Ferrières J, Ruidavets JB, Williams NR, Howard AN. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. *Eur J Clin Invest* 2000; 30: 4-10.
49. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. *Arterioscler Thromb Vasc Biol* 1997; 17: 1067-1073.
50. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. *FEBS Letters* 1998; 423: 57-60.

51. Schmidt H, Schmidt R, Niederkorn K, gradert A, Schumacher M, Watzinger N, Hartung HP, Kostner GM. Paraoxonase PON1 polymorphism Leu-Met54 is associated with carotid atherosclerosis. *Stroke* 1998; 29: 2043-2048.
52. Malin R, Laine S, Rantalaiho V, Wirta O, Pasternack A, Jokela H, Alho H, Koivula T, Lehtimäki T. Lipid peroxidation is increased in paraoxonase L55 homozygotes compared with M-allele carriers. *Free Rad Res* 2001; 34: 477-484.
53. Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques-Vidal P, Bard JM, Cambien F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. *Atherosclerosis* 1996; 126: 299-303.
54. Antikainen M, Murtomäki S, Syväne M, Pahlman R, Tahvanainen E, Jauhiainen M. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. *J Clin Invest* 1996; 98: 883-885.
55. Mackness B, Davies GK, Turlie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI. paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype?. *Arterioscler Thromb Vasc Biol* 2001; 21: 1451-1457.
56. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. *Circulation* 2002; 106: 484-490.
57. Rodrigo L, Hernández AF, López-Caballero JJ, Gil F, Pla A. Immunohistochemical evidence for the expression and induction of paraoxonase in the liver, kidney, lung and brain tissue. Implications for its physiological role. *Chem Biol Interact* 2001; 31: 123-137.
58. Pellin MC, Moretto A, Lotti M, Vilanova E. Distribution and some biochemical properties of rat paraoxonase activity. *Neurotoxicol Teratol* 1990; 12: 611-614.
59. Gil F, Pla A, Gonzalvo MC, Hernández AF, Villanueva E. Rat liver paraoxonase: subcellular distribution and characterization. *Chem Biol Interact* 1993; 87: 149-154.
60. Gil F, Pla A, Gonzalvo MC, Hernández AF, Villanueva E. Partial purification of paraoxonase from rat liver. *Chem Biol Interact* 1993; 87: 69-75.

61. Huang YS, Woods L, Sultatos LG. Solubilization and purification of A-esterase from mouse hepatic microsomes. *Biochem Pharmacol* 1994; 48: 1273-1280.
62. Rodrigo L, Gil F, Hernández AF, Marina A, Vázquez J, Pla A. Purification and characterization of paraoxon hydrolase from rat liver. *Biochem J* 1997; 321: 595-601.
63. Hernández AF, Gonzalvo MC, Gil F, Villanueva E, Pla A. Divergent effects of classical inducers on rat plasma and microsomal fraction paraoxonase and arylesterase. *Environ Toxicol Pharmacol* 1997; 3: 83-86.
64. Gonzalvo MC, Gil F, Hernández AF, Villanueva E, Pla A. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. *Chem Biol Interact* 1997; 105: 169-179-
65. Gonzalvo MC, Gil F, Hernández AF, Rodrigo L, Villanueva E, Pla A. Human liver paraoxonase (PON1): subcellular distribution and characterization. *J Biochem Mol Toxicol* 1998; 12: 61-69
66. Rodrigo L, Gil F, Hernández AF, Pla A. Identification of two rat liver proteins with paraoxonase activity: biochemical evidence for the identity of paraoxonase and arylesterase. *Chem Biol Interact* 1999; 119: 263-275.
67. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. *Arterioscler Thromb Vasc Biol* 1997; 17: 2935-2939.
68. Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. *Atherosclerosis* 1998; 139: 307-315.
69. Esterbauer H, Cheeseman KH. Determination of aldehydic peroxidation products: malondialdehyde and 4-hydroxynonenal. *Methods Enzymol* 1990; 186: 407-421.
70. Chojkier M, Houglum K, Solís-Herruzo J, Brenner DA. Stimulation of collagen gene expression by ascorbic acid in cultured human fibroblasts: a role for lipid peroxidation? *J Biol Chem* 1989; 264: 16957-16962.
71. Cabré M, Ferré N, Folch J, Paternáin JL, Hernández M, Del Castillo D, Joven J, Camps J. Inhibition of hepatic cell nuclear DNA fragmentation by zinc in carbon tetrachloride-treated rats. *J Hepatol* 1999; 31: 228-234.

72. Ferré N, Girona J, Cabré M, Joven J, La Ville A, Masana L, Paternáin JL, Camps J. Hepatic production of apolar aldehydes in rats with carbon tetrachloride-induced cirrhosis. *Mol Cell Biochem* 1999; 198: 57-60.
73. Cabré M, Camps J, Paternáin JL, Ferré N, Joven J. Time-course of changes in hepatic lipid peroxidation and glutathione metabolism in rats with carbon tetrachloride-induced cirrhosis. *Clin Exp Pharmacol Physiol* 2000; 27: 694-699.
74. Cabré M, Camps J, Ferré N, Paternáin JL, Joven J. The antioxidant and hepatoprotective effects of zinc are related to hepatic cytochrome P450 depression and metallothionein induction in rats with experimental cirrhosis. *Int J Vit Nutr Res* 2001; 71: 229-236.
75. Ferré N, Camps J, Paul A, Cabré M, Calleja L, Osada J, Joven J. Effects of high-fat, low-cholesterol diets on hepatic lipid peroxidation and antioxidants in apolipoprotein E-deficient mice. *Mol Cell Biochem* 2001; 218: 165-169.
76. Gasso M, Rubio M, Varela G et al. Effects of s-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. *J Hepatol* 1996; 25: 200-205.
77. Cabre M, Joven J, Camps J. Specific activity of the thiobarbituric acid determination in CCl<sub>4</sub>-induced hepatic injury in rats. *Med Sci Res* 1993; 21: 55-57.
78. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. *Clin Chem* 1993; 39: 561-577.
79. Bruns DE, Huth EJ, Magic E, Young DS. Toward a checklist for reporting studies of diagnostic accuracy of medical tests. *Clin Chem* 2000; 46: 893-895.
80. Pairitz JarviK G, Rozek LS, Brophy VH, hatsukami TS, Ritcher RJ, Schellenberg GD, Furlong CE. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than in *PON1*<sub>192</sub> or *PON1*<sub>55</sub> genotype. *Arterioscler Thromb Vasc Biol* 2000; 20: 2441-2447.
81. Shih DM, Gu L, Hama S, Xia Y-R, Navab M, Fogelman AM, Lusis AJ. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. *J Clin Invest* 1996; 97: 1630-1639.



82. Navab M, Hama HY, Van Lanten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Luscis LJ, Fogelman AM. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. *J Clin Invest* 1997; 99: 2005-2019.
83. Sutherland WHF, Walker RJ, de Jon SA, van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. *Arterioscler Thromb Vasc Biol* 1999; 19: 1340-1347.
84. Jarvik GP, Trevanian Tsai N, Mcinstry LA, Wani R, Brophy VH, Ritcher RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE. Vitamin C and E intake is associated with increased paraoxonase activity. *Arterioscler Thromb Vasc Biol* 2002; 22: 1329-1333.
85. Sabesin SM, Hawkins HL, Kuiken L, Ragland JB. Abnormal plasma lipoproteins and lecitin-cholesterol acyltransferase deficiency in alcoholic liver disease. *Gastroenterology* 1997; 72: 510-518.